Bispecifics in Multiple Myeloma: Payer Perspectives : Episode 12
Emerging BCMA Targeting Bispecifics in Multiple Myeloma
Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.
EP: 1.Multiple Myeloma: Overview of an Evolving Treatment Landscape
EP: 2.Treatment Considerations With Bispecifics in Multiple Myeloma
EP: 3.Where Do Bispecifics Fit in the Multiple Myeloma Treatment Paradigm?
EP: 4.Administering Step-up and Treatment Doses of Bispecifics in Patients With MM
EP: 5.Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma
EP: 6.Multiple Myeloma: Addressing Financial Barriers to Bispecifics
EP: 7.Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics
EP: 8.Long-Term Monitoring for CRS and AEs With Bispecific Therapy
EP: 9.Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting
EP: 10.Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM
EP: 11.Supportive Care Strategies for Patients with MM on Bispecifics Treatment
Now Viewing
EP: 12.Emerging BCMA Targeting Bispecifics in Multiple Myeloma
EP: 13.Non-BCMA Targeting Bispecifics in MM and Future Directions in Care
EP: 14.Reviewing the Approval Process of Teclistamab in Multiple Myeloma
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
